Evaluation of Plasmatic Kisspetin-10 as a Biomarker for Malignancy and Subtype Differentiation in Small Renal Tumours.

Horstmann M, Krause F, Steinbach D, Twelker L, Grimm MO

Urologia internationalis18 Jan 2017Cited by 5 (Europe PMC)

PMID28095383DOI10.1159/000452108PepBankPUB-28095383

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with small renal tumours and controls, the body's own kisspeptin‑10 was detected in plasma of all participants.
In plain wordsIn people with small kidney tumours and controls, the body's own kisspeptin‑10 was found in everyone's blood plasma.
Peptide
Kisspeptin-10
Outcome
Not applicablePlasma Kiss-10 detection
Study
n = 183
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
Kiss-10 was detected in all patients and controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit.
Summary · context
The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2809538301
02HumanEndogenous levelObservational studyOther
In patients with small renal tumours, plasma kisspeptin‑10 was higher than in age-matched controls.
In plain wordsPeople with small kidney tumours had higher levels of the body's own kisspeptin‑10 in blood than controls.
Peptide
Kisspeptin-10
Outcome
IncreasePlasma Kiss-10 level, tumour patients versus controls
Study
n = 183
Comparator
Age-matched controls
Outcome group
Endogenous peptide levels · Cancer
Measurements
Kiss-10 mean
10.04 pmol/l
small renal tumour patients
Kiss-10 mean
6.37 pmol/l
controls
Source sentences
Summary
SRT patients revealed significantly higher Kiss-10 levels than controls (mean value 10.04 vs. 6.37 pmol/l, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit.
Summary · context
The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2809538302
03HumanEndogenous levelObservational studyOther
Plasma kisspeptin‑10 separated all small renal tumours from controls with an ROC area under the curve of 0.82.
In plain wordsMeasuring the body's own kisspeptin‑10 in blood separated kidney tumour patients from controls by ROC analysis.
Peptide
Kisspeptin-10
Outcome
Not applicableROC AUC of plasma Kiss-10, all tumours versus controls
Study
n = 183
Comparator
Age-matched controls
Outcome group
Endogenous peptide levels · Cancer
Measurements
AUC
0.82
all tumours vs controls
Source sentences
Summary
Receiver operating characteristic curve analyses revealed an area under the curve (AUC) of 0.82 for the comparison of all tumours vs. controls (p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit.
Summary · context
The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2809538304
04HumanEndogenous levelObservational studyOther
Among patients with small renal tumours, plasma kisspeptin‑10 differed between subtypes, highest in oncocytomas and lowest in clear cell RCC.
In plain wordsAmong people with small kidney tumours, the body's own kisspeptin‑10 in blood differed by tumour type, highest in oncocytomas.
Peptide
Kisspeptin-10
Outcome
MixedPlasma Kiss-10 level by tumour subtype
Study
n = 143
Comparator
Other tumour subtypes
Outcome group
Endogenous peptide levels · Cancer
Measurements
Kiss-10
11.5 pmol/l
oncocytoma
Kiss-10
9.89 pmol/l
chRCC
Kiss-10
10.01 pmol/l
pRCC
Kiss-10
9.25 pmol/l
ccRCC
Source sentences
Summary
In SRT patients, Kiss-10 was detected at significantly different concentrations between the subgroups (p = 0.021). The highest concentration was observed in those with oncocytomas (11.50 pmol/) followed by chRCC, pRCC and ccRCC patients (9.89, 10.01 and 9.25 pmol/l, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit.
Summary · context
The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2809538303
05HumanEndogenous levelObservational studyOther
Plasma kisspeptin‑10 separated malignant tumours from oncocytomas with an ROC area under the curve of 0.671.
In plain wordsThe body's own kisspeptin‑10 in blood separated cancerous kidney tumours from benign oncocytomas by ROC analysis.
Peptide
Kisspeptin-10
Outcome
Not applicableROC AUC of plasma Kiss-10, malignant tumours versus oncocytomas
Study
n = 143
Comparator
Oncocytomas
Outcome group
Endogenous peptide levels · Cancer
Measurements
AUC
0.671
malignant tumours vs oncocytomas
Source sentences
Summary
an AUC of 0.671 for all malignant tumours vs. oncoytomas (p = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit.
Summary · context
The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2809538305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.